Clinical Trials Logo

Hypertrophic Scarring clinical trials

View clinical trials related to Hypertrophic Scarring.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04756882 Active, not recruiting - Clinical trials for Hypertrophic Scarring

Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars

Start date: November 18, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Background: Scars widen when the overlying musculature pulls apart suture lines. Because Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces temporary muscle paralysis, the purpose of this current study is to evaluate the beneficial effects of Botulinum toxin type A (BTA) on scar formation. Aim of this study: The aim of this study is to evaluate the efficacy and safety of early postoperative Botulinum Toxin type A (BTA) injection on improving vertical or oblique facial surgical scars. Materials and methods: Patients with vertical or oblique forehead lacerations, treated by primary closure, will be enrolled in this study and randomized into two groups: One group (n =6) will receive BTA injection within 5 days of primary closure and the other group (n = 6) will receive no further treatment. Vancouver scar scale (VSS) Scores and wound width will be determined at the 1, 3 and 6 months follow-up visits, along with clinical photographs. Results: Data will be collected, tabulated and statically analyzed. Key words: Botulinum Toxin Type A; facial scarring; wound healing; scar maturation